| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5861379 | EMD SERONO | Chimeric fatty body-pro-GRF analogs with increased biological potency |
May, 2015
(8 years ago) | |
| US6020311 | EMD SERONO | GRF analogs with increased biological potency |
May, 2015
(8 years ago) | |
| US7144577 | EMD SERONO | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
Jul, 2020
(3 years ago) | |
| US8314066 | EMD SERONO | GH secretagogues and uses thereof |
Aug, 2023
(8 months ago) | |
| US8435945 | EMD SERONO | GH secretagogues and uses thereof |
Aug, 2023
(8 months ago) | |
| US7316997 | EMD SERONO | GH secretagogues and uses thereof |
Aug, 2023
(8 months ago) | |
Egrifta is owned by Emd Serono.
Egrifta contains Tesamorelin Acetate.
Egrifta has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Egrifta are:
- US5861379
- US6020311
- US7144577
- US8314066
- US8435945
- US7316997
Egrifta was authorised for market use on 10 November, 2010.
Egrifta is available in powder;subcutaneous dosage forms.
Egrifta can be used as reduction of excess abdominal fat in hiv-infected patients with lipodystrophy.
Drug patent challenges can be filed against Egrifta from 10 November, 2014.
The generics of Egrifta are possible to be released after 14 August, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2015 |
Drugs and Companies using TESAMORELIN ACETATE ingredient
NCE-1 date: 10 November, 2014
Market Authorisation Date: 10 November, 2010
Treatment: Reduction of excess abdominal fat in hiv-infected patients with lipodystrophy
Dosage: POWDER;SUBCUTANEOUS
EGRIFTA family patents
List of large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US5861379 | NA | Chimeric fatty body-pro-GRF analogs with increased biological potency |
May, 2020
(3 years ago) |
Ingredients: TESAMORELIN